cancer diagnostics
-
Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
-
Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
-
Biotech startup using AI to take guesswork out of cancer drug selection raises $70M
Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.
-
Illumina’s $7.1B Grail buyout is challenged by FTC on competitive grounds
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
-
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the test’s reach.
-
Molecular diagnostics is the future of cancer care — if we make it user friendly
Molecular diagnostics companies have laid the foundation for nothing short of a revolution in cancer care — it’s time for the medtech sector to develop tools to make genomic testing accessible to the masses.
-
Pop-up trial sites and the future of personalized oncology care
On the back of that symbolic FDA approval, Foundation Medicine’s Gaurav Singal discussed the latest innovations for expanding access to precision medicine beyond the major academic centers.
-
Liquid biopsy highlights from #ASCO2017
Running low on talking points for your liquid biopsy watercooler chats? Fear not. An education session at ASCO 2017 highlighted some of the latest findings from the field — and we have a recap of that recap here.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Color secures widespread coverage for its hereditary cancer test
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is ‘yes.’
-
With $360M in new financing, Guardant Health prepares to sequence one million cancer patients
Guardant Health has unveiled an ambitious five-year plan to sequence tumor DNA from one million cancer patients. Dubbed “Guardant 1 million,” the push will be financed with $360 million in new financing from a broad syndicate of investors.
-
Grail initiates massive multicenter breast cancer study
The results of the study will serve as a baseline measure for detecting breast cancer in the blood and inform the development of Grail’s pan-cancer screening test.
-
Behind Grail, Illumina’s billion-dollar diagnostics startup
With a billion dollars in private financing and a test projected to generate a terabyte of data per person, Grail has seeded a new category of diagnostics and Big Data. Despite this, the company story shared by CEO Jeff Huber is mostly about people.
-
From Grail to Freenome, liquid biopsies seize the day
Wednesday was just short of a billion-dollar day for liquid biopsy companies, with a $65 million Series A announcement from Freenome and a $900 million Series B close from Illumina spin-out Grail.
-
This CEO has a promising startup but no visa
Deborah Zanforlin founded a cancer diagnostics startup, ConquerX, at just 25-years-of-age. She has journeyed through some of the top U.S. incubator programs, built a technology platform, a prototype, a website and a passionate executive team. What she doesn’t have is the tuition money she needs to stay in the U.S.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
